9 days ago
ARGX
AnalystsDanielle BrillDanielle Brill's Stock Forecasts
AnalystsDanielle Brill
Analyst Ranking
Top 16%
#781 out of 5177 analysts
Average Return
+12.07%
Win Rate
48%42 out of 88
Risk vs Reward
Poor
Good
Danielle Brill's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Uniqure NvQURE | +1,074.35% | $5.42 | $63.65 | 2024-10-09 - 2025-10-09 | Buy |
Palvella Therapeutics IncPVLA | +235.42% | $31.00 | $103.98 | 2025-07-20 - 2026-01-15 | Strong Buy |
Sage Therapeutics IncSAGE | +149.76% | $70.20 | $175.33 | 2017-05-15 - 2018-05-16 | Buy |
Argenx SeARGX | +76.16% | $354.13 | $623.82 | 2023-12-20 - 2024-12-20 | Strong Buy |
Bridgebio Pharma IncBBIO | +66.14% | $45.90 | $76.26 | 2025-07-20 - 2026-01-15 | Strong Buy |
Danielle Brill Analyst Color
Get additional color on Danielle Brill's coverage of popular stocks
9 days ago
NBIX
9 days ago
DNTH
9 days ago
CNTA
9 days ago
BBIO
a month ago
PVLA
2 months ago
IRON
3 months ago
BBIO
3 months ago
ALNY
3 months ago
PVLA
a year ago
SRPT
Danielle Brill's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Argenx SeARGX | 8 | Strong Buy | $1,030.00 | +26.65% | Maintains | 9 days ago |
Tectonic Therapeutic IncTECX | 3 | Strong Buy | $60.00 | +207.53% | Maintains | 9 days ago |
Neurocrine Biosciences IncNBIX | 8 | Strong Buy | $169.00 | +26.73% | Maintains | 9 days ago |
Immunovant IncIMVT | 6 | Hold | $22.00 | -15.38% | Maintains | 9 days ago |
Harmony Biosciences Holdings IncHRMY | 9 | Strong Buy | $45.00 | +23.59% | Maintains | 9 days ago |
Dianthus Therapeutics IncDNTH | 2 | Strong Buy | $63.00 | +43.18% | Maintains | 9 days ago |
Centessa Pharmaceuticals PLCCNTA | 2 | Strong Buy | $33.00 | +47.32% | Maintains | 9 days ago |
Bridgebio Pharma IncBBIO | 3 | Strong Buy | $86.00 | +12.77% | Maintains | 9 days ago |
Alnylam Pharmaceuticals IncALNY | 3 | Strong Buy | $530.00 | +47.53% | Maintains | 9 days ago |
Palvella Therapeutics IncPVLA | 4 | Strong Buy | $190.00 | +82.73% | Maintains | a month ago |
Disc Medicine IncIRON | 6 | Strong Buy | $114.00 | +60.47% | Maintains | 2 months ago |
Upstream Bio IncUPB | 1 | Strong Buy | $47.00 | +52.10% | Initiates Coverage On | 3 months ago |
Jefferson Capital IncJCAP | 1 | Strong Buy | $24.00 | +5.31% | Initiates Coverage On | 6 months ago |
Uniqure NvQURE | 6 | Strong Buy | $52.00 | N/A | Upgrades | a year ago |
Biomarin Pharmaceutical IncBMRN | 1 | Buy | $79.00 | N/A | Reinstates | a year ago |
Regenxbio IncRGNX | 1 | Buy | $18.00 | N/A | Reinstates | a year ago |
Sarepta Therapeutics IncSRPT | 2 | Buy | $150.00 | N/A | Reinstates | a year ago |
Xenon Pharmaceuticals IncXENE | 2 | Buy | $50.00 | N/A | Reinstates | a year ago |
Agios Pharmaceuticals IncAGIO | 2 | Buy | $51.00 | N/A | Reinstates | a year ago |
Biogen IncBIIB | 1 | Buy | $283.00 | N/A | Upgrades | 2 years ago |
Passage Bio IncPASG | 5 | Buy | $100.00 | N/A | Maintains | 2 years ago |
Ptc Therapeutics IncPTCT | 6 | Buy | $55.00 | N/A | Maintains | 2 years ago |
Kyntra Bio IncKYNB | 2 | Buy | $875.00 | N/A | Upgrades | 3 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Vertex Pharmaceuticals IncVRTX | 1 | Hold | N/A | N/A | Initiates Coverage On | 5 years ago |
Acadia Pharmaceuticals IncACAD | 2 | Buy | $35.00 | N/A | Downgrades | 5 years ago |
Global Blood Therapeutics IncGBT | 4 | Hold | $50.00 | N/A | Downgrades | 5 years ago |
Gw Pharmaceuticals PLCGWPH | 1 | Hold | N/A | N/A | Initiates Coverage On | 5 years ago |
Zogenix IncZGNX | 1 | Hold | N/A | N/A | Initiates Coverage On | 5 years ago |
Alder Biopharmaceuticals IncALDR | 2 | Buy | $28.00 | N/A | Assumes | 8 years ago |
Sage Therapeutics IncSAGE | 1 | Buy | $82.00 | N/A | Initiates Coverage On | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.